- Oxidative Stress Modulates the Expression Pattern of Peroxiredoxin-6 in Peripheral Blood Mononuclear Cells of Asthmatic Patients and Bronchial Epithelial Cells
-
Shim HJ, Park SY, Kwon HS, Song WJ, Kim TB, Moon KA, Choi JP, Kim SJ, Cho YS
- KMID: 2471234
- Allergy Asthma Immunol Res.
- 2020 May;12(3):523-536.
- doi: 10.4168/aair.2020.12.3.523
PURPOSE: Reduction-oxidation reaction homeostasis is vital for regulating inflammatory conditions and its dysregulation may affect the pathogenesis of chronic airway inflammatory diseases such as asthma. Peroxiredoxin-6, an important intracellular anti-oxidant... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of the 26S and 20S Proteasomes by the Site-specific Inhibitors
-
Woo KM
- KMID: 2437766
- Soonchunhyang Med Sci.
- 2018 Jun;24(1):47-54.
- doi: 10.0000/sms.2018.24.1.47
OBJECTIVE: The study was performed to establish the purification processes of both 26S and 20S proteasomes, also to investigate the inhibitory properties and patterns of two different proteasome inhibitors on... -
- CITED
-
- Close
- SHARE
-
- Close
- Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
-
Lee DM, Kim IY, Seo MJ, Kwon MR, Choi KS
- KMID: 2389293
- Exp Mol Med.
- 2017 Aug;49(8):e365.
- doi: 10.1038/emm.2017.112
The proteasome inhibitor, bortezomib, is ineffective against many solid tumors. Nutlin-3 is a potent antagonist of human homolog of murine double minute 2/p53 interaction exhibiting promising therapeutic anti-cancer activity. In... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of a Proteasome Inhibitor on Cardiomyocytes in a Pressure-Overload Hypertrophy Rat Model: An Animal Study
-
Kim IS, Jo WM
- KMID: 2381896
- Korean J Thorac Cardiovasc Surg.
- 2017 Jun;50(3):144-152.
- doi: 10.5090/kjtcs.2017.50.3.144
BACKGROUND: The ubiquitin-proteasome system (UPS) is an important pathway of proteolysis in pathologic hypertrophic cardiomyocytes. We hypothesize that MG132, a proteasome inhibitor, might prevent hypertrophic cardiomyopathy (CMP) by blocking the... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
-
Lee HS, Min CK
- KMID: 2350969
- Korean J Intern Med.
- 2016 Sep;31(5):809-819.
- doi: 10.3904/kjim.2016.110
Multiple myeloma is an incurable malignant plasma cell-originating cancer. Although its treatment outcomes have improved with the use of glucocorticoids, alkylating drugs, and novel agents, including proteasome inhibitors (bortezomib and... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibitory Effect of Apocynin on Proteasome Inhibition-Induced Apoptosis in Differentiated PC12 Cells
-
Kang JH, Han SW, Han JH, Kim DE, Lee CS
- KMID: 2163256
- J Korean Neurol Assoc.
- 2016 May;34(2):116-123.
- doi: 10.17340/jkna.2016.2.5
BACKGROUND: The dysfunction of the proteasome system has been implicated in neuronal degeneration. Apocynin, a specific inhibitor for nicotinamide adenine dinucleotide phosphate oxidase, has anti-inflammatory and anti-oxidant effects. However, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Bortezomib-induced Drug Eruption Presenting as Multiple Plaques on the Trunk
-
Choe YS, Kim EJ, Na JI
- KMID: 2245828
- Korean J Dermatol.
- 2016 Jan;54(1):47-51.
Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one... -
- CITED
-
- Close
- SHARE
-
- Close
- HIF-1alpha Upregulation due to Depletion of the Free Ubiquitin Pool
-
Kim J, So D, Shin HW, Chun YS, Park JW
- KMID: 2344170
- J Korean Med Sci.
- 2015 Oct;30(10):1388-1395.
- doi: 10.3346/jkms.2015.30.10.1388
Hypoxia-inducible factor 1alpha (HIF-1alpha), which transactivates a variety of hypoxia-induced genes, is rapidly degraded under nomoxia through the hydroxylation-ubiquitination-proteasome pathway. In this study, we addressed how HIF-1alpha is stabilized by... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma
-
Lim JH, Hwang KB, Lim BH, Jeong YH, Sohn KC, Kim TH
- KMID: 2448488
- Korean J Pancreas Biliary Tract.
- 2015 Jul;20(3):136-139.
- doi: 10.15279/kpba.2015.20.3.136
Bortezomib is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Recently, several case reports about acute pancreatitis caused by Bortezomib were published in the international literature.... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel Agents for Treatment of Multiple Myeloma
-
Kim HJ
- KMID: 2082582
- Korean J Med.
- 2015 Mar;88(3):252-257.
- doi: 10.3904/kjm.2015.88.3.252
Multiple myeloma (MM) is a neoplasm of clonal plasma cells that closely interacts with the bone marrow (BM) microenvironment. The overall survival of patients with MM has improved dramatically in... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture
-
Han SH, Kim JS, Woo JH, Jeong SJ, Shin JS, Ahn YS, Kim JM
- KMID: 2352796
- Yonsei Med J.
- 2015 Jan;56(1):112-123.
- doi: 10.3349/ymj.2015.56.1.112
PURPOSE: Although the proteasome inhibitor known as bortezomib can modulate the inflammatory process through the nuclear factor-kappa B signaling pathway, the immunomodulatory effect of pre-incubated bortezomib has not been fully... -
- CITED
-
- Close
- SHARE
-
- Close
- Bis is Induced by Oxidative Stress via Activation of HSF1
-
Yoo HJ, Im CN, Youn DY, Yun HH, Lee JH
- KMID: 2285539
- Korean J Physiol Pharmacol.
- 2014 Oct;18(5):403-409.
- doi: 10.4196/kjpp.2014.18.5.403
The Bis protein is known to be involved in a variety of cellular processes including apoptosis, migration, autophagy as well as protein quality control. Bis expression is induced in response... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Refractory Antibody-mediated Rejection with Bortezomib in a Kidney Transplant Recipient: A Case Report
-
Lee JY, Yoo JY, Kwon SH, Jeon JS, Noh H, Han DC, Song D, Jin SY
- KMID: 2202536
- J Korean Soc Transplant.
- 2014 Jun;28(2):87-90.
- doi: 10.4285/jkstn.2014.28.2.87
Antibody-mediated rejection (ABMR) is associated with poor renal allograft survival. It shows poor response to conventional treatment with plasmapheresis, rituximab, and intravenous immunoglobulin. Bortezomib, a proteasome inhibitor used for treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Transcriptional Upregulation of Plasminogen Activator Inhibitor-1 in Rat Primary Astrocytes by a Proteasomal Inhibitor MG132
-
Cho KS, Kwon KJ, Jeon SJ, Joo SH, Kim KC, Cheong JH, Bahn GH, Kim HY, Han SH, Shin CY, Yang SI
- KMID: 1502511
- Biomol Ther.
- 2013 Mar;21(2):107-113.
Plasminogen activator inhibitor-1 (PAI-1) is a member of serine protease inhibitor family, which regulates the activity of tissue plasminogen activator (tPA). In CNS, tPA/PAI-1 activity is involved in the regulation... -
- CITED
-
- Close
- SHARE
-
- Close
- Medaka Fish Parkinson's Disease Model
-
Matsui H, Gavinio R, Takahashi
- KMID: 2134999
- Exp Neurobiol.
- 2012 Sep;21(3):94-100.
- doi: 10.5607/en.2012.21.3.94
The teleost fish has been widely used in creating neurodegenerative models. Here we describe the teleost medaka fish Parkinson's disease (PD) models we developed using toxin treatment and genetic engineering.... -
- CITED
-
- Close
- SHARE
-
- Close
- Proteasome-Inhibitor-Based Primary Therapy for Antibody-Mediated Rejection in a Renal Transplant Recipient
-
Park SJ, Yu H, Kang SH, Baek SD, Baek CH, Jeong JH, Park SK
- KMID: 2264162
- Korean J Med.
- 2011 Dec;81(6):780-785.
Donor-specific anti-human leukocyte antigen antibodies (DSA) following kidney transplantation predict the evolution of humoral rejection and reduced graft survival. Rapid, complete elimination of DSA during antibody-mediated rejection (AMR) is rarely... -
- CITED
-
- Close
- SHARE
-
- Close
- Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines
-
Cheong HJ, Lee KS, Woo IS, Won JH, Byun JH
- KMID: 2167538
- Cancer Res Treat.
- 2011 Jun;43(2):124-130.
PURPOSE: Current chemotherapeutics for treating locally advanced or metastatic soft tissue sarcomas (STS) are limited. Accordingly, the present in vitro study was conducted to evaluate the effects of treatment of... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination Therapy of Bortezomib (PS-341) and SAHA (Vorinostat) in Non-Small Cell Lung Cancer Cell Lines
-
Park MY, Kim DR, Park JS, Cho YJ, Lee SW, Yoon HI, Lee JH, Lee CT
- KMID: 2199908
- J Lung Cancer.
- 2010 Dec;9(2):77-84.
- doi: 10.6058/jlc.2010.9.2.77
PURPOSE: The recent introduction of targeted therapy for non-small cell lung cancer (NSCLC) has changed the paradigm of lung cancer chemotherapy. However, only a small portion of NSCLC patients received... -
- CITED
-
- Close
- SHARE
-
- Close
- Selective Susceptibility of Human Dopaminergic Neural Stem Cells to Dopamine-Induced Apoptosis
-
Jeon SM, Cheon SM, Bae HR, Kim JW, Kim SU
- KMID: 1460760
- Exp Neurobiol.
- 2010 Dec;19(3):155-164.
- doi: 10.5607/en.2010.19.3.155
Dysfunctions of ubiquitin-proteasome system and toxicity of dopamine have been known as the key mechanisms in the pathogenesis of Parkinson's disease (PD) and proteasome inhibitors are widely used in experimental... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Bortezomib-Associated Cutaneous Lymphocytic Vasculitis
-
Lee KJ, Kim JE, Park HJ, Lee JY, Cho BK
- KMID: 2247734
- Korean J Dermatol.
- 2009 Dec;47(12):1392-1396.
Bortezomib (Velcade(R)) is a newly developed chemotherapeutic agent that is mainly used for the treatment of multiple myeloma. It is a selective and reversible inhibitor of proteasome, which is a... -
- CITED
-
- Close
- SHARE
-
- Close
